Synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
=== Thermal proteome profiling (TPP) === Thermal proteome profiling (also, Cellular Thermal Shift Assay) is recently popularized strategy to infer ligand-protein interactions from shifts in protein thermal stability induced by ligand binding. In a typical assay setup, protein-containing samples are exposed to a ligand of choice, then those samples are aliquoted and heated to separate individual temperature points. Upon binding to a ligand, a protein's thermal stability is expected to increase, so ligand-bound proteins will be more resistant to thermal denaturation. After heating, the amount of non-denatured protein remaining is analyzed using quantitative proteomics and stability curves are generated. Upon comparison to an untreated stability curve, the treated curve is expected to shift to the right, indicating that ligand-induced stabilization occurred. Historically, thermal proteome profiling has been assessed using a western blot against a known target of interest. With the advent of high resolution Orbitrap mass spectrometers, this type of experiment can be executed on a proteome-wide scale and stability curves can be generated for thousands of proteins at once. Thermal proteome profiling has been successfully performed in vitro, in situ, and in vivo. When coupled with mass spectrometry, this technique is referred to as the Mass Spectrometry Cellular Thermal Shift Assay (MS-CETSA).
The development of high-throughput sequencing in recent years has allowed for the development of extensive databases for different modifications and edits of RNA. RADAR (Rigorously Annotated Database of A-to-I RNA editing) was developed in 2013 to catalog the vast variety of A-to-I sites and tissue-specific levels present in humans, mice, and flies. The addition of novel sites and overall edits to the database are ongoing. The level of editing for specific editing sites, e.g. in the filamin A transcript, is tissue-specific. The efficiency of mRNA-splicing is a major factor controlling the level of A-to-I RNA editing. Interestingly, ADAR1 and ADAR2 also affect alternative splicing via both A-to-I editing ability and dsRNA binding ability.
In November 1998, Layne Staley recorded a cover of Pink Floyd's "Another Brick in the Wall" with the supergroup Class of '99. The song was featured on the soundtrack to the 1998 horror/sci-fi film, The Faculty. After they toured as part of Cantrell's solo band in 1998, Sean Kinney and Queensrÿche guitarist Chris DeGarmo formed a new band called Spys4Darwin. Mike Inez and Sponge lead vocalist Vin Dombroski joined the supergroup soon after. The band released their first and only album in 2001, a 6-track EP entitled Microfish. In June 2001, Mike Inez joined Zakk Wylde's Black Label Society for the remaining dates of Ozzfest, following the departure of bassist Steve Gibb for medical reasons. Inez joined the band again for their West Coast and Japanese tour in 2003. By 2002, Cantrell had finished work on his second solo album, Degradation Trip. Written in 1998, the album's lyrical content focused heavily on what Cantrell regarded as the demise of Alice in Chains, which still remained evident as the album approached its June 2002 release. However, in March that year, Cantrell commented, "We're all still around, so it's possible [Alice in Chains] could all do something someday, and I fully hope someday we will."
Upon hearing of the assassination of socialist candidate Jorge Eliécer Gaitán, many poor workers saw the death of Gaitán as a political assassination orchestrated by the rich. Workers began rioting and destroying the Colombian capital of Bogotá, leading to the death of 4,000 people. When news of the death of Gaitán reached the countryside, the local militias were furious and immediately started a civil war, known as La Violencia. Joined by fellow leftists, a brutal war was fought for over 10 years, leading to the death of 200,000 people and the destruction of much of the country, resulting in a peace settlement and the changing of power from the Colombian Conservative Party to the Colombian Liberal Party and the Colombian Communist Party in 1958. As La Violencia wound down, most self-defense and guerrilla units composed of Liberal Party supporters were demobilized. At the same time, some former liberals and active communist groups continued operating in several rural enclaves. One of the Liberal bands was a group known as the "Fuerzas Armadas Revolucionarias de Colombia" (Revolutionary Armed Forces of Colombia), or FARC, formed by Pedro Antonio Marín in 1964. The FARC was founded out of fighters who were unhappy with the peace settlement. The goal of the FARC, among other things, was land redistribution that would benefit poor peasant farmers like Marín, along with the desire to establish a socialist state. In 1958, an exclusively bipartisan political alternation system, known as the National Front, resulted from an agreement between the Liberal and Conservative parties.
== Drug pricing issue and exit in the Swiss market == In July 2025, Roche withdrew Lunsumio from the Swiss market following failed price negotiations with the Swiss Federal Office of Public Health (BAG). The drug had been available since February 2023 through a special "Early Access" program that allowed reimbursement before complete clinical data was available. Under this arrangement, Roche initially covered treatment costs until efficacy was demonstrated, after which the remaining therapy could exceed 100,000 Swiss francs. When Swissmedic extended the temporary authorization in February 2025 due to still-missing complete clinical data from Phase III studies, Roche rejected the previously negotiated pricing model and demanded higher prices. The BAG refused to modify the agreement, citing concerns that exceptions would set a precedent for other pharmaceutical companies and demanding additional efficacy evidence despite the drug showing positive effects in Phase II studies. According to Swissmedic pricing data, a single 60-mg dose (two vials) of Lunsumio costs over 7,000 Swiss francs. The withdrawal was announced to oncologists on July 1, 2025, affecting approximately 24 patients annually who suffer from follicular lymphoma—a slowly progressing cancer of the lymph nodes with about 500 new cases per year in Switzerland. Roche also refused to provide individual case reimbursements—a standard Swiss mechanism for exceptional medical situations.
Sources: en.wikipedia.org
In May–June 1897, Thomson investigated whether or not the rays could be deflected by an electric field. Previous experimenters had failed to observe this, but Thomson believed their experiments were flawed because their tubes contained too much gas. Thomson constructed a Crookes tube with a better vacuum. At the start of the tube was the cathode from which the rays projected. The rays were sharpened to a beam by two metal slits – the first of these slits doubled as the anode, the second was connected to the earth. The beam then passed between two parallel aluminium plates, which produced an electric field between them when they were connected to a battery. The end of the tube was a large sphere where the beam would impact on the glass, created a glowing patch. Thomson pasted a scale to the surface of this sphere to measure the deflection of the beam. Any electron beam would collide with some residual gas atoms within the Crookes tube, thereby ionizing them and producing electrons and ions in the tube (space charge); in previous experiments this space charge electrically screened the externally applied electric field. However, in Thomson's Crookes tube the density of residual atoms was so low that the space charge from the electrons and ions was insufficient to electrically screen the externally applied electric field, which permitted Thomson to successfully observe electrical deflection.
== History == The brewery started as a small, casual pub in the alleyways of Gyeongnidan in Seoul. The idea to start the pub was inspired by Tudor's article in The Economist, which claimed: "brewing remains just about the only useful activity at which North Korea beats the South." The pub began selling Bill's Pale Ale, The Booth's first brew, along with a small selection of pizza. After realizing how crucial the cold chain transportation system was to maintaining the quality and flavor of beer, the owners established the first cold chain import and distribution system, The Booth Cold Chain. This was soon importing beers from Mikkeller, Evil Twin, To Øl, and 8 Wired. Two crowdfunding campaigns titled Equity for Booth were launched, in September 2015 and February 2017.
May 25, 2009: Thailand Thailand's economy shrank more than expected in the first quarter, contracting the most in a decade, plunging the nation into recession. GDP shrank 7.1% in the last quarter of 2008, followed by another shrinking of 4.2% in the first quarter of 2009. According to the Singapore branch of Macquarie Group, the Thai economy is expected to recover in the fourth quarter of 2009.
== Prognosis == The availability of treatments that modify the course of multiple sclerosis beginning in the 1990s, known as disease-modifying therapies (DMTs), has improved prognosis. These treatments can reduce relapses and slow progression, but there is no cure. Before the advent of these medications, it took around 15 years before relapsing-remitting MS progressed to secondary progressive MS (which has associated mobility issues). With these medications, the progression is slower to 40 years. The prognosis of MS depends on the subtype of the disease, and there is considerable individual variation in the progression of the disease. In relapsing MS, the most common subtype, a 2016 cohort study found that after a median of 16.8 years from onset, one in ten needed a walking aid, and almost two in ten transitioned to secondary progressive MS, a form characterized by more progressive decline. With treatments available in the 2020s, relapses can be eliminated or substantially reduced. However, "silent progression" of the disease still occurs. In addition to secondary progressive MS (SPMS), a small proportion of people with MS (10–15%) experience progressive decline from the onset, known as primary progressive MS (PPMS). Most treatments have been approved for use in relapsing MS; there are fewer treatments with lower efficacy for progressive forms of MS. The prognosis for progressive MS is worse, with faster accumulation of disability, though with considerable individual variation.
The stringed crowns and the trays used in manual sorting are shown in the figure. The destination tray is moved step by step in the direction of the arrow. The crowns are transferred in groups from the slots of the source tray into the all opposite slots of the destination tray. The transfers are directed by computer and the products are identified by the positions of the crowns occupied on the final strings. A fast automatic sorter machine had also been described. The sorter is outlined in the figure. It has two sets of aligned tubes. The lower ones are step by step moving in the direction showed by the arrow and the coin-like units are dropped from the upper source tubes into the lower destination ones. The tubes may serve as reaction vessels too. A software had also been developed that can direct sorting if not a full combinatorial library is synthesized only a set of its components are prepared that are picked out from the full library.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.